Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Recruiting now

Conditions studied: Neovascular Glaucoma

In brief

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).

Key facts

Study ID

NCT04519619

Run by

Bayer

People needed

480

Starts

2020-11-27

Expected to finish

2028-06-30

Last updated by the study team

2026-06-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of NVG
• Patients who have received IVT-AFL treatment according to Japanese labeling.

You may not qualify if…

• Patients who are contraindicated based on approved label
• Diagnosis of other indication

Where it is running

• Many locations — Multiple Locations, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.